Sensorion (FR0012596468 – ALSEN), a pioneering biotechnology company specializing in hearing loss disorders, has unveiled new positive findings from its SENS-401 Phase 2a clinical trial. The data, focusing on the preservation of residual hearing following cochlear implantation in adult patients, was presented by Professor Stephen O’Leary, M.D., Ph.D., at the 17th International Conference on Cochlear Implants and Other Implantable Technologies (CI2024) in Vancouver, Canada, on July 13, 2024.
Key highlights include significant differences in hearing loss between the SENS-401 treated group and the control group, with notable results sustained up to 14 weeks post-implantation. Specifically, patients treated with SENS-401 exhibited a mean hearing loss of 19 dB at 500 Hz, compared to 32 dB in the untreated control group (N=8). Similar positive outcomes were observed across other frequencies (250, 500, and 750 Hz).
Nawal Ouzren, CEO of Sensorion, commented, “These findings underscore the clinical significance of SENS-401 in preserving residual hearing post-cochlear implantation, supporting its potential to enhance patient outcomes in this critical procedure.”
